July 2020
Investor Presentation
NASDAQ: OPCH
Disclaimer
This communication may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) the completion of the quarterly close process in respect of the preliminary financial information included in this presentation; (ii) changes in laws and regulations applicable to our business model; (iii) changes in market conditions and receptivity to our services and offerings; (iv) results of litigation; (v) the loss of one or more key payers; (vi) the spread and impact of the COVID-19 pandemic and our responses thereto; and (vii) our ability to realize further synergies from the merger (discussed herein). For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our reports as filed with the SEC.
Any forward-looking statement made by us in this presentation is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. All of the forward-looking statements herein are qualified by these cautionary statements.
This communication is neither an offer to sell nor a solicitation of an offer to buy any securities, including our common stock, and may not be relied upon by you in evaluating the merits of investing in the common stock and as to the actual return on an investment in the common stock. This communication shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. We have filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents we have filed with the SEC for more complete information about us and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may also be obtained, when available, from BofA Securities, Inc., Attn: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255, email: dg.prospectus_requests@bofa.com
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
2
Disclaimer (Cont.)
Preliminary Financial Data
The preliminary financial information included in this communication is subject to completion of our quarter-end close procedures and further financial review. Actual results may differ from these estimates as a result of the completion of our quarter-end closing procedures, review adjustments and other developments that may arise between now and the time such financial information for the period is finalized. As a result, these estimates are preliminary, may change and constitute forward-looking information and, as a result, are subject to risks and uncertainties. These preliminary estimates should not be viewed as a substitute for full interim financial statements prepared in accordance with United States generally accepted accounting principles ("GAAP"), and they should not be viewed as indicative of our results for any future period.
Note Regarding Use of Non-GAAP Financial Measures
In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), we are also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company's liquidity. In addition, our definition of Adjusted EBITDA may not be comparable to similarly titled non- GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by us, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, and restructuring, acquisition, integration and other expenses. As part of restructuring, acquisition, integration and other expenses, we may incur significant charges such as the write down of certain long−lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of our business operations and facilitates comparisons to our historical operating results. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see the appendix.
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
3
Offering Summary
Issuer | Option Care Health, Inc. |
Ticker / Exchange | OPCH / NASDAQ |
Security Type | Follow-on offering of common stock |
Base Offering Size | $350 million |
Primary / Secondary | $125 million primary / $225 million secondary |
Over-allotment Option | 15% (100% secondary) |
Use of Primary Proceeds | Repay a portion of our senior secured second lien PIK toggle floating rate notes due 2027 |
Expected Pricing Date | Tuesday, July 21, 2020 (after market close) |
Lock-Up Provision | 90 Days |
Selling Stockholder | HC Group Holdings I, LLC |
Active Bookrunner | BofA Securities |
Passive Joint Bookrunners | Barclays / Deutsche Bank / Goldman Sachs / J.P. Morgan / Morgan Stanley / |
SunTrust Robinson Humphrey / William Blair / Lake Street | |
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
4
Option Care Health at a Glance
45
states
96%
of U.S. population covered
- Nation's largest independent provider of home and alternate site infusion services, licensed in all 50 states
- Clinical leadership and technology-enabled patient- centered model
National Footprint | 2Q'20 Results | |
$2.7bn+ | $740.8 | |
(in millions) | ||
combined 2019 revenue1 | ||
~2,900 | ||
skilled clinicians | ||
Top 10 | $54.6 | |
payers all in-network | ||
500+ | Revenue | Adj. EBITDA |
frontline selling resources
Option Care Health is reimagining the infusion care experience
for patients, customers and employees
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
5
1Based on 2019 combined revenue in consideration of the merger between Option Care and Bioscrip
Leading Position in a Large and Growing Market1
$100 B
$13 B
$2.7 B2
U.S. Infusion Market
Includes: hospitals,
physician outpatient
offices, SNFs and home infusion
U.S. Home Infusion Market
Lowest-cost setting; growing penetration
of overall market
Option Care Health
Largest independent provider
U.S. Competitive Landscape - Home
22%
$13B
61%17%
/
- Two national providers represent less than half of the market
- Significant market opportunity with 800+ infusion companies in the U.S.
The U.S. Home Infusion Market is Growing by an
Estimated 5-7% Per Year
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004 | 6 |
1Market share based on management estimates |
2Based on 2019 combined revenue in consideration of the merger between Option Care and Bioscrip
On the Right Side of Healthcare Trends
The Home is the Disruptive Service Model within the Infusion Market
Remicade infusion example | IG infusion example |
$10,000
~77% cost savings
$2,300 | |||
Outpatient Hospital | |||
Home Infusion | |||
Setting |
Average cost for one infusion therapy cycle of Remicade (includes cost of drug)
$9,800 ~44% cost savings
$5,500
The right place,
the right team, and
the right time.
Outpatient Hospital | Home Infusion |
Setting | |
Average cost for one infusion therapy cycle (includes cost of drug)
Care is moving from the Hospital… | …to the Home |
• Higher cost setting | • $4 billion potentially saved annually by shifting care to the |
home or alternate site | |
• Potential for significant waste | |
• Lower cost, safer site of care; lower risk of infection | |
• Less desirable outcomes, including infections and | |
preventable deaths | • Patient preference, resulting in better quality of life |
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
7
Investment Highlights
- Only independent national provider in network with all national payers
- Right side of healthcare - independent, low cost care setting, patient centric
- Large, growing and highly fragmented market
- Significant merger-related cost synergies achieved ahead of schedule
- Improved free cash flow generation
- Balanced payer mix with mostly commercial reimbursement… low "pen stroke" risk
- Seasoned management team
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
8
Strength in Diversity
Therapy Revenue Split
~40%
~60%
Acute
Chronic
- No therapy category represents more than 20% of revenue
- Broad portfolio of chronic and acute therapies including more than 50 limited distribution therapies
Payer Mix1
~12%
~88%
Commercial
Government
- No payer more than 16% of revenue
- Low direct government reimbursement risk
- Productive payer relationships given independence
Balanced revenue base across therapies and payers
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
9
1Commercial also includes Medicare Advantage, Managed Medicaid and Patient Pay
Acute vs Chronic Therapy Portfolios
Acute | Chronic | |
~40% | % of Net Revenue | ~60% |
50-70% | Product Margin | 10-25% |
Shorter, typically | Average length of | Longer, typically months |
1-12 weeks | treatment | or for life |
Anti-infectives, | Immunoglobulin, | |
nutritional support, | Therapies | inflammatory, other |
inotropic therapy | chronic conditions | |
Branded, specialty | ||
Generic, branded | Type of drug utilized | biologic, limited |
distribution | ||
Hospital Case | ||
Management / Physician | Typical referral source | Physician / Specialist |
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
10
Merger Integration Update: Synergy Capture Roadmap
Achieved targeted synergy run rate in Q2 2020 ahead of schedule
Network Savings $20-$25M
18-24 months to realization
Optimize assets to best serve the market
SG&A Optimization
12-18 months to realization
Streamline corporate and administrative functions
Procurement Synergies
9 -12 months to realization
Maximize procurement savings and combined organization
3Q 2019
$35-$40M $Annualized60M+ Net Savings1
$10-$15M
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
11
1Represents high-confidence level synergies estimate before cost to implement
Recent Developments
- COVID-19Impact
- As expected, the pandemic has negatively affected new patient referrals
- However, we experienced an increase in patient transfers from hospital and outpatient settings which positively affected revenues
- We continue to collaborate with payers and health systems to transition patients into the home or one of our alternate treatment sites to receive vital infusion therapy
- Q2 2020 Preliminary Financial Results
1
- Integration Update
- Fully achieved the articulated goal of at least $60 million in run-rate net cost synergies in Q2 2020
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004 | 12 |
1Adjusted EBITDA is a non-GAAP measure. Please refer to slide 3 and the appendix for further details and a reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure. |
Roadmap for Growth
Realize synergy opportunities
- Execution of defined short and longer-term integration synergies
- Utilize improved capital structure and liquidity position to create investment plan
Optimize and expand offerings
- Alignment of acute and chronic sales activity against top market opportunities
- Therapeutic-levelmarket penetration and potential to increase share
Capture the ambulatory setting
- Optimization of Ambulatory Infusion Suite footprint and business model
- Implement strategies to drive utilization
Add value to payer relationships
- Partnerships and site-of-care initiatives to drive patient volume
- Opportunities to expand and evolve economic relationship
Invest in growth enablers
- Technology investments (internal and customer facing applications)
- Additional opportunities to leverage clinical expertise
- Data analytics and outcome reporting
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
13
Proven, Experienced Leadership Team
John Rademacher
Chief Executive Officer
- Joined Option Care in 2015 as COO and was appointed CEO in 2018
- Served as President and General Manager at Cardinal Health Ambulatory Care and Nuclear and Pharmacy Services divisions
- Former President at CareAllies and COO of the CIGNA Behavioral Health business
Mike Shapiro
Chief Financial Officer
- Joined Option Care in 2015 as CFO
- Served as SVP and CFO of Catamaran Corporation and as CFO of Rexnord Corporation
- Spent fifteen years with Baxter International, holding multiple positions of increasing responsibility
- Began career at Deloitte and is a CPA (inactive)
Harriet Booker
Chief Operating Officer
- Joined Option Care Health in August 2019 as COO following the merger with Bioscrip, where she held the same position since 2018
- Former Executive Vice President of Sales and COO for Coram/CVS Specialty Infusion Services
- Prior to that, served in various senior and executive-level roles at Walgreens - Option Care
Rich Denness
Chief Commercial Officer
- Joined Option Care Health in August 2019 as Chief Strategy Officer following the merger with Bioscrip, where he served as Chief Commercial Officer since 2018
- Former GM at Schering- Plough, President at IVAX Laboratories, VP, Neurology at UCB, and CEO at Vycor Medical
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
14
Improved Capital Structure
$ in millions | ||||||||
Pro Forma Capitalization | ||||||||
As of | As Adjusted | |||||||
3/31/20 | Adj. | 3/31/20 | ||||||
Cash and Cash Equivalents | $77 | -- | $77 | |||||
$150mm ABL Revolver | -- | -- | -- | |||||
First Lien Term Loan | 923 | -- | 923 | |||||
Second Lien Notes | 412 | (118)1 | 294 | |||||
Total Debt | $1,335 | $1,217 | ||||||
Net Debt | $1,258 | $1,140 | ||||||
Key Highlights
- Simple capital structure
- Relatively long maturity runway
- Continued strong liquidity
- All debt covenant-lite, no financial maintenance "triggers"
- No borrowings on ABL revolver
- Accelerates Option Care towards target leverage ratio of under 4.0x
The Proposed Equity Raise Will Further Improve Option Care's Leverage Profile and Capitalization
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004 | 15 |
1Less underwriting discount and $2.4 million prepayment premium, before other expenses. |
Appendix
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
16
Quarterly Reconciliation Between GAAP And Non- GAAP Measures
$ in thousands
Three Months | ||
Ended | ||
June 30, 2020 | ||
2020 | ||
Consolidated net loss | $ | (7,668) |
Interest expense, net | 31,432 | |
Income tax expense (benefit) | 470 | |
Depreciation and amortization expense | 19,969 | |
Consolidated EBITDA | 44,203 | |
EBITDA adjustments | ||
Stock-based incentive compensation | 661 | |
Restructuring, acquisition, integration and other | 9,759 | |
Consolidated adjusted EBITDA | $ | 54,623 |
©2020 Option Care Health, Inc. All rights reserved. 19OCH00004
17
Attachments
- Original document
- Permalink
Disclaimer
Option Care Health Inc. published this content on 19 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2020 21:00:00 UTC